Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2693 Following Multiple Subcutaneous Dose Administration in Healthy Participants

NCT05107336 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05107336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05107336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2693 Following Multiple Subcutaneous Dose Administration in Healthy Participants
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 25, 2021
Completion date
March 21, 2023
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants